Full text is available at the source.
Abstract
A robust market for compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) emerged due to supply-side challenges and high costs.
- The market dynamics for GLP-1 RAs have shifted since shortages of semaglutide and tirzepatide ended.
- High costs and limited insurance coverage may continue to influence the accessibility of GLP-1 RAs.
- Understanding current market trends is essential for evaluating the availability of these medications.
Simplified